General Information of the Protein
| Protein ID |
PT01637
|
||||
|---|---|---|---|---|---|
| Protein Name |
Phospholipase A2
|
||||
| Secondarily Protein Name |
Group IB phospholipase A2
Phosphatidylcholine 2-acylhydrolase 1B
|
||||
| Gene Name |
PLA2G1B
|
||||
| Secondarily Gene Name |
PLA2
PLA2A
PPLA2
|
||||
| Sequence |
MKLLVLAVLLTVAAADSGISPRAVWQFRKMIKCVIPGSDPFLEYNNYGCYCGLGGSGTPVDELDKCCQTHDNCYDQAKKLDSCKFLLDNPYTHTYSYSCSGSAITCSSKNKECEAFICNCDRNAAICFSKAPYNKAHKNLDTKKYCQS
Show/Hide
|
||||
| Organism |
Homo sapiens, Human
|
||||
| Protein Classification |
Enzyme
>
Hydrolase
|
||||
| Function |
Secretory calcium-dependent phospholipase A2 that primarily targets dietary phospholipids in the intestinal tract (PubMed:1420353, PubMed:10681567, PubMed:17603006). Hydrolyzes the ester bond of the fatty acyl group attached at sn-2 position of phospholipids (phospholipase A2 activity) with preference for phosphatidylethanolamines and phosphatidylglycerols over phosphatidylcholines (PubMed:1420353, PubMed:10681567, PubMed:17603006). May play a role in the biosynthesis of N-acyl ethanolamines that regulate energy metabolism and inflammation in the intestinal tract. Hydrolyzes N-acyl phosphatidylethanolamines to N-acyl lysophosphatidylethanolamines, which are further cleaved by a lysophospholipase D to release N-acyl ethanolamines (By similarity). May act in an autocrine and paracrine manner (PubMed:7721806, PubMed:25335547). Upon binding to the PLA2R1 receptor can regulate podocyte survival and glomerular homeostasis (PubMed:25335547). Has anti-helminth activity in a process regulated by gut microbiota. Upon helminth infection of intestinal epithelia, directly affects phosphatidylethanolamine contents in the membrane of helminth larvae, likely controlling an array of phospholipid-mediated cellular processes such as membrane fusion and cell division while providing for better immune recognition, ultimately reducing larvae integrity and infectivity (By similarity).
Show/Hide
|
||||
| Uniprot ID |
Show/Hide
|
||||
| Ensembl ID | |||||
| HGNC ID | |||||
| Subcellular Location |
Secreted
|
||||
Clinical Information about the Protein
Target 1 ( Phospholipase A2 (PLA2G1B) )
| Target Type | Successful Target | ||||
|---|---|---|---|---|---|
| Disease | 8 Target-related Diseases | 8 | |||
| 1 | Synthesis disorder [ICD-11: 5C52-5C59] | ||||
| 2 | Leishmaniasis [ICD-11: 1F54] | ||||
| 3 | Arthritis [ICD-11: FA20] | ||||
| 4 | Metabolic syndrome x [ICD-11: 5C50-5D2Z] | ||||
| 5 | Snakebite [ICD-11: N.A.] | ||||
| 6 | Cardiovascular disease [ICD-11: BA00-BE2Z] | ||||
| 7 | Arteriosclerosis [ICD-11: BD40] | ||||
| 8 | Rheumatoid arthritis [ICD-11: FA20] | ||||
| Approved Drug(s) | 2 Approved Drugs | 2 | |||
| 1 | Cholic Acid | Approved | |||
| 2 | Miltefosine | Approved | |||
| Clinical Trial Drug(s) | 4 Clinical Trial Drugs | 4 | |||
| 1 | MANOALIDE | Phase 2 | |||
| 2 | URSOLIC ACID | Phase 2 | |||
| 3 | Varespladib | Phase 2 | |||
| 4 | Rilapladib | Phase 1 | |||
| Discontinued Drug(s) | 3 Discontinued Drugs | 3 | |||
| 1 | Darapladib | Discontinued in Phase 3 | |||
| 2 | SB-435495 | Discontinued in Phase 1 | |||
| 3 | YM-26734 | Terminated | |||